Harsh Michael 4

What Happened Harsh Michael, a director of ENDRA Life Sciences, acquired 60,324 shares on January 21, 2026 as an award/vesting of restricted stock units (RSUs). The Form 4 lists the acquisition at $0.00 per share (total reported cash consideration $0), reflecting conversion of RSUs to common stock rather than an open-market purchase or sale.

Key Details

• Transaction date: January 21, 2026 (reported on Form 4 filed January 23, 2026) — filing appears timely.
• Transaction type/code: Award/Grant/Other acquisition (A).
• Shares acquired: 60,324 common shares; reported price: $0.00; reported cash consideration: $0.
• Holdings after transaction: not specified in the provided filing data.
• Footnotes: F1 notes holdings include unvested RSUs; F2 states these RSUs convert one-for-one to common stock and vested in full on January 21, 2026.
• No 10b5-1 plan, tax withholding, or immediate sale was reported in the provided excerpt.

Context This was a compensation-related vesting of RSUs converting to common shares, not a market purchase or sale. Such awards are common for directors and do not by themselves indicate the insider buying or selling in the open market. The Form 4 reports the mechanical conversion (price $0) rather than the market value of the shares on the vesting date.